HomeMarketsSharesSinopharm Group Co. Ltd.

Trade Sinopharm Group Co. Ltd. - 1099 CFD

Market is not available at the momentMarket information is presented
as of 2026-04-28 07:46:42
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.1
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
HK$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.017691 %
(-HK$3.54)

Trade size with leverage ~ HK$20,000.00

Money from leverage ~ $HK$19,000.00


-0.01769%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
HK$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.004227 %
(-HK$0.85)

Trade size with leverage ~ HK$20,000.00

Money from leverage ~ $HK$19,000.00


-0.00423%
Overnight funding adjustment time21:00 (UTC)
CurrencyHKD
Min traded quantity10
Margin5.00%
Stock exchangeHong Kong
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close18.4
Open18.35
1-Year Change5.46%
Day's Range18.25 - 18.55

Trade Sinopharm Group Co. Ltd. - 1099 CFD

About SINOPHARM HOLDING CO LTD

Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SINOPHARM HOLDING CO LTD revenues increased 14% to RMB521.05B. Net income applicable to common stockholders increased 8% to RMB7.76B. Revenues reflect Retail Sales - Total increase of 20% to RMB28.57B. Net income was partially offset by Impairment of Intangibles increase from RMB265M to RMB606.9M (expense), Bank and other borrowings increase of 10% to RMB2.87B (expense).

Latest shares articles

BioNTech flag on a tall pole waving against a blue sky with light clouds
BioNTech stock forecast: Co-founder exit, 2026 guidance cut
BioNTech is a German biotech company whose shares have faced pressure since March 2026 amid planned leadership changes, weaker-than-expected revenue guidance, and broader tariff-related uncertainty. Past performance is not a reliable indicator of future results. Read third-party BNTX price targets.
5 hours ago
Allianz logo mounted on top of a modern office building
Allianz stock forecast: Record profit, buyback, softer guidance
Allianz is a German insurer and asset manager that reported record 2025 operating profit of €17.4bn and launched a €2.5bn share buyback, while its 2026 guidance missed analyst forecasts. Past performance is not a reliable indicator of future results. Explore third-party ALV price targets.
5 hours ago
Siemens logo mounted on the exterior wall of a modern building
Siemens stock forecast: EPS guidance, Q1 profit
Siemens is a German industrial group whose shares have been supported by stronger Q1 results, higher 2026 EPS guidance, and recent progress in its rail and infrastructure businesses. Past performance is not a reliable indicator of future results. Explore third-party SIE price targets.
10:17, 27 April 2026
Bayer logo displayed on a circular sign
Bayer stock forecast: Guidance reaffirmed, litigation in focus
Bayer is a German life sciences company whose 2026 outlook centres on reaffirmed guidance, ongoing Roundup litigation, and the potential effect of US pharmaceutical tariffs. Past performance is not a reliable indicator of future results. Explore third-party BAYN price targets and technical analysis.
10:09, 27 April 2026
Related News
Reuters NewsEurope
04:11 (UTC), 27 April 2026
Sinopharm Group touches 6-month low as quarterly profit slips
Reuters NewsEurope
01:22 (UTC), 27 April 2026
Sinopharm Group Posts Qtrly Total Operating Revenue RMB 140.77 Billion
Public TechnologiesEurope
08:32 (UTC), 24 April 2026
Sinopharm publishes 2025 annual report
Public TechnologiesEurope
09:12 (UTC), 23 April 2026
Sinopharm subsidiary CNMDC posts Q1 operating profit down 20.4%
Public TechnologiesEurope
12:12 (UTC), 22 April 2026
Sinopharm unit CNCM posts Q1 net profit RMB 474.3 million, up 3.3%
Public TechnologiesEurope
11:29 (UTC), 21 April 2026
Sinopharm Accord Q1 net profit falls 12.4% to RMB 287 million
Reuters NewsEurope
04:00 (UTC), 17 April 2026
Hong Kong corporate earnings week ahead

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-19
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

2025-06-29
p*******

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading